Literature DB >> 9186000

Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.

J Liu1, M J Spence, P M Wallace, K Forcier, I Hellström, R E Vestal.   

Abstract

Human oncostatin M (OM) is a M(r) 28,000 glycoprotein that has been shown to regulate cell proliferation and differentiation. The biological activities of OM can be mediated by two different heterodimeric receptor complexes, the leukemia inhibitory factor (LIF)/OM shared receptor and the OM-specific receptor. In this study, we have examined the growth-regulatory effect of OM on 10 breast cancer cell lines derived from human tumors. The cellular proliferation of seven of these breast cancer cell lines was inhibited by OM. The three cell lines that did not respond to OM treatment lacked the expression of OM receptors. The growth-inhibitory activity of OM is examined further in the H3922 breast cancer cell line, which expresses the high-affinity OM receptor at a relatively higher level. We found that the cellular proliferation of H3922 cells was induced strongly by extrogenous epidermal growth factor (EGF), EGF-like factor, and basic fibroblast growth factor. The proliferative activities of these growth factors can be abolished totally by cotreatment of H3922 cells with OM. Treatment of H3922 cells with OM for 24 h did not block EGF binding or the induction of EGF receptor tyrosine phosphorylation. This finding suggests that OM interferes with the mitogenic signal at steps distal to the EGF receptor. Examination of proto-oncogene expression demonstrated that OM down-regulates the c-myc gene in H3922 cells. The biological effects reported herein are not shared by the OM-related cytokines interleukin 6 or LIF, as demonstrated by the inability of these proteins to inhibit cell growth or modulate c-myc gene expression in breast cancer cells. Additionally, the high-affinity binding of labeled OM cannot be displaced by LIF. Together, these data suggest that OM is a growth inhibitor for breast cancer cells. The inhibitory activity is mediated predominantly through the OM-specific receptor, and activation of this receptor abrogates growth factor stimulation and down-regulates the c-myc proto-oncogene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186000

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

2.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

3.  A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor.

Authors:  Srinivas Chollangi; Timothy Mather; Karla K Rodgers; John D Ash
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

Review 4.  Constitutive activation of STAT3 in breast cancer cells: A review.

Authors:  Kasturi Banerjee; Haluk Resat
Journal:  Int J Cancer       Date:  2015-11-28       Impact factor: 7.396

5.  Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.

Authors:  Ryan G Holzer; Randall E Ryan; Matt Tommack; Eric Schlekeway; Cheryl L Jorcyk
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Association of the oncostatin m receptor gene polymorphisms with papillary thyroid cancer in the korean population.

Authors:  Il Ki Hong; Young Gyu Eun; Dae Han Chung; Kee Hwan Kwon; Deog Yoon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-12-15       Impact factor: 3.372

Review 7.  Bioengineering embryonic stem cell microenvironments for the study of breast cancer.

Authors:  Nurazhani Abdul Raof; Bridget M Mooney; Yubing Xie
Journal:  Int J Mol Sci       Date:  2011-11-08       Impact factor: 5.923

Review 8.  GP130 Cytokines in Breast Cancer and Bone.

Authors:  Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancers (Basel)       Date:  2020-01-31       Impact factor: 6.639

Review 9.  Exercise-induced myokines and their effect on prostate cancer.

Authors:  Jin-Soo Kim; Daniel A Galvão; Robert U Newton; Elin Gray; Dennis R Taaffe
Journal:  Nat Rev Urol       Date:  2021-06-22       Impact factor: 14.432

Review 10.  Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.

Authors:  Maria M Caffarel; Nicholas Coleman
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.